Could a daily supplement help kids with obesity? new trial tests postbiotic ABB C3
NCT ID NCT06309121
First seen Mar 29, 2026 · Last updated Jun 19, 2026 · Updated 14 times
Summary
This study tests whether a daily postbiotic supplement called ABB C3 can safely reduce body fat and improve blood sugar in 70 children and teens with obesity. Half the participants take the supplement for 3 months, the other half take a placebo, and then everyone can take the supplement for another 3 months. Researchers will monitor body fat, blood markers, and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY, CHILDHOOD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Sant Joan de Déu
Barcelona, Barcelona, 08950, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Postbiotic blend ABB C3 (dietary supplement)
What this could lead to
If it works, this could offer a safe, easy-to-take supplement to help young people with obesity reduce body fat and improve metabolic health.
What could go wrong
This is a small, early-stage trial with only 70 participants. The supplement may not work better than placebo, and any benefits might be modest or temporary.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.